Gradient Investments LLC Purchases 10,497 Shares of Insulet Corporation $PODD

Gradient Investments LLC raised its position in shares of Insulet Corporation (NASDAQ:PODD) by 17.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,161 shares of the medical instruments supplier’s stock after buying an additional 10,497 shares during the quarter. Gradient Investments LLC owned about 0.10% of Insulet worth $19,658,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Sage Mountain Advisors LLC increased its stake in shares of Insulet by 4.6% in the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 33 shares in the last quarter. Glenmede Investment Management LP boosted its stake in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after acquiring an additional 35 shares in the last quarter. Curi Capital LLC boosted its stake in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. WINTON GROUP Ltd grew its holdings in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd grew its holdings in Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 39 shares during the period.

Insulet Trading Down 0.7%

Shares of NASDAQ PODD opened at $227.10 on Monday. The firm’s 50 day moving average price is $252.11 and its 200-day moving average price is $292.83. Insulet Corporation has a 52-week low of $216.49 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The company has a market cap of $15.99 billion, a PE ratio of 64.89, a P/E/G ratio of 1.36 and a beta of 1.42.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same quarter last year, the firm earned $1.15 earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PODD. UBS Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. Sanford C. Bernstein cut their price target on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Canaccord Genuity Group reduced their price objective on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Oppenheimer lowered their price objective on Insulet from $365.00 to $300.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Finally, Barclays reissued an “underweight” rating and issued a $286.00 target price on shares of Insulet in a report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $354.24.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.